{"id":"NCT00242580","sponsor":"Novartis Pharmaceuticals","briefTitle":"A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib","officialTitle":"A 24-month Randomized, Double-masked, Sham Controlled, Multicenter, Phase IIIB Study Comparing Photodynamic Therapy With Verteporfin (Visudyne速) Plus Two Different Dose Regimens of Intravitreal Triamcinolone Acetonide (1 mg and 4 mg) Versus Visudyne速 Plus Intravitreal Pegaptanib(Macugen速) in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-09","primaryCompletion":"2008-01","completion":null,"firstPosted":"2005-10-20","resultsPosted":"2011-05-02","lastUpdate":"2016-03-31"},"enrollment":111,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Macular Degeneration","Choroidal Neovascularization"],"interventions":[{"type":"DRUG","name":"Verteporfin photodynamic therapy","otherNames":["Visudyne"]},{"type":"DRUG","name":"Pegaptanib","otherNames":["Macugen"]},{"type":"DRUG","name":"Triamcinolone acetonide","otherNames":["Kenalog-40速"]}],"arms":[{"label":"Verteporfin and Triamcinolone 1 mg","type":"EXPERIMENTAL"},{"label":"Verteporfin and Triamcinolone 4 mg","type":"EXPERIMENTAL"},{"label":"Verteporfin and Pegaptanib","type":"ACTIVE_COMPARATOR"}],"summary":"To evaluate the safety and efficacy of the combination treatments in wet age-related macular degeneration. The combination treatment consists of verteporfin photodynamic therapy and either triamcinolone acetonide or pegaptanib added as an intravitreal injection.","primaryOutcome":{"measure":"Percentage of Participants Who Lose Less Than 15 Letters of Best Corrected Visual Acuity (BCVA) at 12 Months From Baseline.","timeFrame":"Baseline to Month 12","effectByArm":[{"arm":"Verteporfin + 1 mg Triamcinolone","deltaMin":59.4,"sd":null},{"arm":"Verteporfin + 4 mg Triamcinolone","deltaMin":63.4,"sd":null},{"arm":"Verteporfin + Pegaptanib","deltaMin":71.1,"sd":null}],"pValues":[]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":5},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":["http://www.novartisclinicaltrials.com/etrials/DiseaseID83/Age-Related-Macular-Degeneration-clinical-trials.go"]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":32},"commonTop":["CATARACT (Study eye)","EYE HEMORRHAGE (Study eye)","AMD PROGRESSION (Fellow eye)","AMD PROGRESSION (Study eye)","HYPERTENSION"]}}